Menopause & perimenopause — symptom management and HRT
Bedside summary
Menopause is the permanent cessation of menstruation (diagnosed retrospectively after 12 months of amenorrhoea), average age ~51; perimenopause is the preceding transition of fluctuating hormones and symptoms. Common symptoms: vasomotor (hot flushes, night sweats), sleep disturbance, mood/cognitive changes, genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms) and reduced bone density. Diagnosis is clinical in women over 45 with typical symptoms (no routine hormone testing needed); FSH may help under 45 or where uncertain. Hormone replacement therapy (HRT) is the most effective treatment for vasomotor and urogenital symptoms and protects bone; the regimen depends on whether the woman has a uterus (needs a progestogen for endometrial protection) and her menstrual status. Premature ovarian insufficiency (< 40 years) warrants HRT at least to the natural age of menopause.
Red flags
- Postmenopausal bleeding or unscheduled/persistent bleeding on HRT — investigate for endometrial cancer
- New focal neurology, severe headache, or chest pain/leg swelling on oral HRT (stroke/VTE)
- Breast lump / strong breast cancer history (affects HRT suitability)
- Premature ovarian insufficiency (< 40) — needs HRT and bone/cardiovascular protection
- Severe low mood / suicidality in perimenopause
- Severe osteoporosis / fragility fracture
Assessment
Differential diagnosis
- Perimenopause / menopause (clinical)
- Premature ovarian insufficiency (< 40 years)
- Thyroid disease (hyper/hypothyroidism mimicking flushes/mood/menstrual change)
- Pregnancy (amenorrhoea in perimenopause)
- Anxiety/depression, other causes of mood/sleep disturbance
- Other causes of flushing (carcinoid, phaeochromocytoma, medication, alcohol)
- Abnormal uterine bleeding from endometrial pathology (investigate postmenopausal/irregular bleeding)
Investigations
- Clinical diagnosis in women >= 45 with typical symptoms — routine FSH/hormone testing NOT required
- FSH (raised) to support diagnosis if < 45 years, atypical, or for suspected premature ovarian insufficiency (two readings 4-6 weeks apart if < 40)
- Thyroid function if symptoms overlap; consider other tests per differential
- Investigate any postmenopausal bleeding or unscheduled bleeding on HRT (ultrasound +/- endometrial biopsy) to exclude endometrial cancer
- Assess cardiovascular risk, VTE risk, breast and migraine history before HRT; blood pressure, BMI
- Bone health / fracture risk assessment (FRAX, DEXA) where indicated, esp. early menopause
Management
- Confirm menopause clinically; assess symptom burden and impact, and individual risk factors (VTE, breast cancer, cardiovascular, migraine)
- Offer HRT as first-line for vasomotor symptoms unless contraindicated, after discussing benefits/risks (individualised, shared decision)
- Choose regimen: with uterus -> oestrogen + progestogen (sequential if perimenopausal/still bleeding; continuous combined if postmenopausal >12 months) for endometrial protection; without uterus -> oestrogen alone
- Prefer transdermal oestrogen (patch/gel) where VTE/cardiovascular risk, migraine, or patient preference — lower VTE and stroke risk than oral
- Use micronised progesterone or levonorgestrel IUS for progestogen component (IUS also gives contraception); counsel that HRT is not contraceptive
- Add vaginal (local) oestrogen for genitourinary symptoms — can be used alone or alongside systemic HRT, long-term, with minimal systemic absorption
- Non-hormonal options if HRT declined/contraindicated: SSRIs/SNRIs or clonidine for flushes, CBT; vaginal moisturisers/lubricants; newer NK3-receptor antagonists (e.g. fezolinetant) where available
- Premature ovarian insufficiency: offer HRT (or combined contraceptive) at least until the natural age of menopause (~51) for symptom and bone/cardiovascular protection
- Review at 3 months then annually; reassess benefits/risks; no arbitrary upper time limit — individualise; manage bleeding and side effects
Drugs & doses
Disposition
Complications & pitfalls
- Osteoporosis and fragility fractures (oestrogen deficiency)
- Genitourinary syndrome of menopause (recurrent UTI, dyspareunia)
- Cardiovascular disease risk changes; reduced quality of life, mood disturbance
- HRT-related: small increased breast cancer risk (combined, duration-dependent), VTE (oral > transdermal), stroke (oral), endometrial hyperplasia if unopposed oestrogen with a uterus
- Premature ovarian insufficiency sequelae if untreated
Exam pearls
- Diagnose menopause clinically in women over 45 — do not routinely check hormone levels.
- HRT is the most effective treatment for vasomotor and urogenital symptoms and protects bone.
- A woman with a uterus needs a progestogen with her oestrogen to protect the endometrium.
- Transdermal oestrogen carries lower VTE/stroke risk than oral — prefer it where there is vascular/VTE/migraine risk.
- Local vaginal oestrogen treats genitourinary symptoms safely long-term and can be combined with systemic HRT.
- Always investigate postmenopausal or unscheduled bleeding to exclude endometrial cancer.
- Treat premature ovarian insufficiency with HRT at least until the usual age of menopause; HRT is not a contraceptive.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.